Literature DB >> 1802900

Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects.

M C Heng1, S G Allen.   

Abstract

In this article we describe the immunocytochemical and electron microscopic findings in five patients with toxic epidermal necrolysis. They indicate the occurrence of necrotic keratinocytes with nuclear disintegration associated with apposed dendritic cells with the nuclear chromatin configuration of T lymphocytes. These findings, including the presence of blebbing of the keratinocytes and membrane defects associated with cytoplasmic processes from these apposed lymphoid cells, fit known electron microscopic criteria that suggest the involvement of T lymphocyte-mediated cytolysis of drug-altered target keratinocytes in toxic epidermal necrolysis. The effector cell appears to be a dendritic subset, with the phenotypic characteristics (CD3+, CD4-, CD8+, CD2+, DR+) of a T cell subset. There is some evidence that tumor necrosis factor alpha, secreted by activated macrophages, may play a role in necrolysis of the epidermis. The dramatic response of our patients to cyclophosphamide, which is known to inhibit cell-mediated cytotoxicity by inhibiting both the recognition and lethal hit stages, together with the rapid regrowth of the epidermis within 4 days to a week in patients who received adequate dosage of the drug, supports the preceding concepts.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1802900     DOI: 10.1016/s0190-9622(08)80969-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

Review 1.  Skin manifestations of drug allergy.

Authors:  Michael R Ardern-Jones; Peter S Friedmann
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

2.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

Review 3.  Drug-induced severe skin reactions. Incidence, management and prevention.

Authors:  P Wolkenstein; J Revuz
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

4.  Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider.

Authors:  David Aguiar; Roberto Pazo; Ignacio Durán; Josefa Terrasa; Antonio Arrivi; Herminio Manzano; Javier Martín; Julio Rifá
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

Review 5.  Allergic emergencies encountered by the dermatologist. Severe cutaneous adverse drug reactions.

Authors:  P Wolkenstein; J Revuz
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 10.817

Review 6.  Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Authors:  Thomas Harr; Lars E French
Journal:  Orphanet J Rare Dis       Date:  2010-12-16       Impact factor: 4.123

Review 7.  Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions.

Authors:  Shih-Chi Su; Wen-Hung Chung
Journal:  Toxins (Basel)       Date:  2014-01-03       Impact factor: 4.546

Review 8.  Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review.

Authors:  Rohini Arora; Rajesh K Pande; Shikha Panwar; Vivek Gupta
Journal:  Indian J Crit Care Med       Date:  2021-05

Review 9.  Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective.

Authors:  Bernard Yu-Hor Thong
Journal:  Asia Pac Allergy       Date:  2013-10-31

Review 10.  Interventions for toxic epidermal necrolysis.

Authors:  S Majumdar; M Mockenhaupt; J- Roujeau; A Townshend
Journal:  Cochrane Database Syst Rev       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.